RxDoctor Payments DataLook up a doctor →

Karim Chamie, MD

Urology · Los Angeles, CANPI 1962478420

Payments from drug & device makers

$4,322,949in general payments, 2019–2025

Across 346 payments — averaging $12,494 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2.7M
  • Astellas US Technologies$1M
  • Urogen Pharma, Inc.$299K
  • Pfizer$100K
  • Johnson & Johnson$70K
  • AstraZeneca$56K
  • plus $110K from 21 others
$47,012in research payments, 2019–2025

Across 4 payments — averaging $11,753 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$45K
  • F. Hoffmann-la Roche AG$1K
  • Urogen Pharma, Inc.$352

What the payments were for

  • Consulting fees$169,64058%
  • Speaking & faculty fees$87,80630%
  • Travel & lodging$23,5648%
  • Food & beverage$9,7733%
  • Education$780%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,322,949 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$684,230
Medicare patients
565
Services billed
7,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron34$37,702
MyrbetriqMirabegron15$19,999
Tamsulosin Hcl113$1,559
Finasteride52$629
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim27$88
Ciprofloxacin Hcl17$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$6,223$19,99915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,324 urology providers in California.

Other urology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →